WO2020246777A1 - 이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법, 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법 및 노니 열매 추출물 또는 이의 분획물의 용도 - Google Patents
이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법, 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법 및 노니 열매 추출물 또는 이의 분획물의 용도 Download PDFInfo
- Publication number
- WO2020246777A1 WO2020246777A1 PCT/KR2020/007155 KR2020007155W WO2020246777A1 WO 2020246777 A1 WO2020246777 A1 WO 2020246777A1 KR 2020007155 W KR2020007155 W KR 2020007155W WO 2020246777 A1 WO2020246777 A1 WO 2020246777A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- fraction
- noni fruit
- ethanol
- fruit extract
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 137
- 244000131360 Morinda citrifolia Species 0.000 title claims abstract description 105
- 235000017524 noni Nutrition 0.000 title claims abstract description 104
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 95
- 238000000034 method Methods 0.000 title claims abstract description 64
- 239000011149 active material Substances 0.000 title abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 187
- 239000002904 solvent Substances 0.000 claims abstract description 39
- 238000000605 extraction Methods 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000002708 enhancing effect Effects 0.000 claims description 50
- 230000036039 immunity Effects 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 239000008213 purified water Substances 0.000 claims description 34
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 239000013543 active substance Substances 0.000 claims description 20
- ZVXWFPTVHBWJOU-AWQYILTISA-N (1s,4as,5r,7as)-5-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C(C(O)=O)=CO1 ZVXWFPTVHBWJOU-AWQYILTISA-N 0.000 claims description 18
- DGDWCRWJRNMRKX-DILZHRMZSA-N Asperulosidic acid Chemical compound O([C@H]1[C@H]2[C@@H](C(=CO1)C(O)=O)[C@@H](O)C=C2COC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGDWCRWJRNMRKX-DILZHRMZSA-N 0.000 claims description 18
- DGDWCRWJRNMRKX-UHFFFAOYSA-N Asperulosidinsaeure Natural products CC(=O)OCC1=CC(O)C(C(=CO2)C(O)=O)C1C2OC1OC(CO)C(O)C(O)C1O DGDWCRWJRNMRKX-UHFFFAOYSA-N 0.000 claims description 18
- VKWWRUZYBNTDHM-AXECJBQYSA-N Deacetylasperulosidic acid Natural products OCC1=C[C@H](O)[C@H]2[C@@H]1[C@H](OC[C@H]3O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]3O)OC=C2C(=O)O VKWWRUZYBNTDHM-AXECJBQYSA-N 0.000 claims description 18
- BZPMXJKRKXDRID-UOIKKKDVSA-N Scandoside Natural products OC[C@H]1O[C@@H](O[C@H]2CC=C([C@@H]3[C@@H](O)C=C(CO)[C@H]23)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O BZPMXJKRKXDRID-UOIKKKDVSA-N 0.000 claims description 18
- IBIPGYWNOBGEMH-DILZHRMZSA-N asperuloside Chemical compound O([C@@H]1OC=C2C(=O)O[C@H]3C=C([C@@H]1[C@H]32)COC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBIPGYWNOBGEMH-DILZHRMZSA-N 0.000 claims description 18
- COUXBBBIXWWAEP-AGUBZPQCSA-N asperuloside Natural products CC(=O)OCC1=C[C@@H]2OC(=O)C3=CO[C@@H](OC[C@H]4O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]4O)[C@H]1[C@H]23 COUXBBBIXWWAEP-AGUBZPQCSA-N 0.000 claims description 18
- AHFAQKUDQUDLNP-AGUBZPQCSA-N asperulosidic acid Natural products CC(=O)OCC1=C[C@H](O)[C@H]2[C@@H]1[C@H](OC[C@H]3O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]3O)OC=C2C(=O)O AHFAQKUDQUDLNP-AGUBZPQCSA-N 0.000 claims description 18
- 229920001282 polysaccharide Polymers 0.000 claims description 17
- 239000005017 polysaccharide Substances 0.000 claims description 17
- 230000036541 health Effects 0.000 claims description 15
- 239000000469 ethanolic extract Substances 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 5
- 229940079593 drug Drugs 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 235000013402 health food Nutrition 0.000 abstract description 3
- 239000000470 constituent Substances 0.000 abstract description 2
- 230000006866 deterioration Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- 235000013305 food Nutrition 0.000 description 12
- 150000004804 polysaccharides Chemical class 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000005227 gel permeation chromatography Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000006433 tumor necrosis factor production Effects 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 230000036737 immune function Effects 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 230000001747 exhibiting effect Effects 0.000 description 6
- 230000003308 immunostimulating effect Effects 0.000 description 6
- 235000020729 noni extract Nutrition 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- -1 iridoides Natural products 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004373 Pullulan Substances 0.000 description 3
- 229920001218 Pullulan Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 235000019423 pullulan Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229920003002 synthetic resin Polymers 0.000 description 3
- 239000000057 synthetic resin Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000008898 Morinda citrifolia Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229940068517 fruit extracts Drugs 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000010421 standard material Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Definitions
- the present invention relates to a method for preparing a noni fruit extract or a fraction thereof containing high iridoid, a method for preparing a noni fruit extract or a fraction thereof containing a high immunostimulating active substance, and a use of a noni fruit extract or a fraction thereof, and more specifically, A method for preparing a noni fruit extract or a fraction thereof containing high iridoid comprising the step of preparing a noni fruit extract using ethanol in a concentration range as an extraction solvent, a method for preparing a noni fruit extract or a fraction thereof containing a high immune enhancing active substance, and the above A pharmaceutical composition for improving immunity comprising an extract or a fraction thereof, a health functional food composition comprising the same composition, a method for enhancing immunity using the extract or a fraction thereof, and a drug for preventing or treating diseases related to immunity enhancement or immunity reduction In preparation, the use of the extract or a fraction thereof is provided.
- Noni is an evergreen shrub belonging to the genus Morinda citrifolia. It is rich in vitamins A and C, and contains physiologically active substances such as flavonoids, iridoides, and alkaloids.
- Polynesians of the South Pacific Noni has been used for edible and therapeutic functions for a long time, and it is a tropical plant that is drawing attention as a health food as it is still used as a raw material for juice and raw material (powder).
- Iridoid discovered in 2009, is a unique plant chemical that is made to defend itself by external environmental factors. It is mainly found in medicinal plants, and helps improve immune function such as skin aging, high blood pressure, and diabetes. 19 kinds of ingredients have been reported as ingredients that give them.
- the inventors of the present invention efficiently extract deacetylasperulosidic acid (DAA), asperulosidic acid (ASPA), and asperuloside (ASP) among the iridoide compounds from noni fruit. It was intended to develop a method of extraction, and when ethanol of a specific concentration range is used as an extraction solvent, a noni fruit extract containing a high content of the three kinds of iridoide compounds can be prepared, and the extract prepared by this method or its It was confirmed that the fraction exhibited excellent efficacy in enhancing immunity, and the present invention was completed.
- DAA deacetylasperulosidic acid
- ASPA asperulosidic acid
- ASP asperuloside
- Republic of Korea Patent Publication No. 10-2009-0072555 discloses a method for producing a concentrate of noni fruit, but this only suggests a method for effectively removing noni's peculiar imitation or off-flavor. There is no suggestion for a method for efficiently extracting the above three types of iridoid compounds or immune enhancing active substances from fruit.
- An object of the present invention is to provide a method for efficiently extracting iridoid from noni.
- Another object of the present invention is to provide a composition for enhancing immunity comprising a noni fruit extract or a fraction thereof.
- Another object of the present invention is to provide a method for enhancing immunity using a noni fruit extract or a fraction thereof.
- Another object of the present invention is to provide a use of a noni fruit extract or a fraction thereof in the manufacture of a medicament for preventing or treating diseases associated with immune enhancement or lowering of immune function.
- Another object of the present invention is to provide a method for efficiently extracting an immune enhancing active substance from noni.
- the present invention provides a method for preparing a noni fruit extract or a fraction thereof containing high iridoid containing the following steps:
- the ethanol of step b) may be 20 (w/w)% to 50 (w/w)% ethanol.
- the extraction in step c) may be agitated extraction.
- the preparation method may further include d) filtering and concentrating the extract to prepare a concentrate.
- the iridoid is deacetylasperulosidic acid (DAA), asperulosidic acid (ASPA), and asperuloside (ASP). ) It may be one or more selected from the group consisting of.
- the present invention also provides a pharmaceutical composition for improving immunity and / or a health functional food composition comprising a noni fruit extract or a fraction thereof.
- the present invention provides a method for enhancing immunity, comprising administering an effective amount of a noni fruit extract or a fraction thereof to an individual in need thereof.
- the present invention also provides a use of a noni fruit extract or a fraction thereof in the manufacture of a medicament for preventing or treating diseases associated with immune enhancement or immune function decline.
- the extract may be prepared using 5 (w/w)% to 50 (w/w)% ethanol as an extraction solvent.
- the fraction may be a purified water fraction of 5 (w/w)% to 50 (w/w)% ethanol extract.
- the fraction may contain a polysaccharide having a molecular weight of 10 kDa or more.
- the present invention also provides a method for preparing a noni fruit extract or a fraction thereof containing a high immunostimulating active substance comprising the following steps:
- the preparation method may further include the step of d) fractionating the obtained extract into purified water.
- the immunostimulating active material may be an iridoide and a polysaccharide having a molecular weight of 10 kDa or more.
- the iridoid is deacetylasperulosidic acid (DAA), asperulosidic acid (ASPA), and asperuloside (ASP). ) It may be one or more selected from the group consisting of.
- the manufacturing method of the noni fruit extract containing high iridoid and the method of preparing the noni fruit extract containing high immune promoting active substance of the present invention include three types of iridoide compounds (DAA, ASPA) from noni fruit using ethanol in a specific concentration range as an extraction solvent. And ASP) can be efficiently extracted, and since ethanol is used as an extraction solvent, it is the most environmentally friendly and economical in food processing.
- the composition for enhancing immunity of the present invention contains a polysaccharide having a molecular weight of 10 kDa or more, which is a substantially effective substance, at a high concentration, and thus exhibits excellent efficacy in enhancing immunity.
- FIG. 1 is a schematic diagram showing a method for producing a noni fruit extract of the present invention.
- Figure 2 is a graph showing the analysis of the total iridoide content of noni fruit extract according to the extraction solvent.
- Figure 3 shows the information of the HPLC profile of 30 (w / w)% ethanol
- Figure 4 is a graph showing the amount of TNF- ⁇ production measured after each solvent extract was treated with the macrophage cell line RAW264.7.
- Figure 5 is a schematic diagram showing a method for producing a fraction of the noni fruit extract of the present invention.
- FIG. 6 is a graph showing the amount of TNF- ⁇ produced after treating each fraction with the macrophage line RAW264.7.
- Figure 7 shows the GPC chromatography of pullulan (pullulan) used as a standard material, (B) shows the GPC chromatography of the purified water fraction (Frc-01).
- iridoid is known as a useful physiologically active ingredient found in noni, but research on a method for efficiently extracting it is insufficient.
- the inventors of the present invention efficiently extract deacetylasperulosidic acid (DAA), asperulosidic acid (ASPA), and asperuloside (ASP) among the iridoide compounds from noni fruit. It was intended to develop a method of extraction, and when ethanol of a specific concentration range was used as an extraction solvent, a noni fruit extract containing a high content of the three kinds of iridoide compounds could be prepared, and the extract prepared by this method or its It was confirmed that the fraction exhibited excellent efficacy in enhancing immunity, and the present invention was completed.
- DAA deacetylasperulosidic acid
- ASPA asperulosidic acid
- ASP asperuloside
- the present invention a) the step of crushing the noni fruit; b) adding 10 (w/w)% to 95 (w/w)% ethanol of 5 to 15 times the weight of the pulverized product to the pulverized product; And c) extracting the extract at 60° C. to 80° C. for 1 to 8 hours to prepare an extract. It provides a method for producing a noni fruit extract or fractions thereof containing high iridoid.
- extract used in the present invention refers to an extract obtained by extracting the noni fruit, more preferably a dried noni fruit, a dilution or concentrate of the extract, a dried product obtained by drying the extract, and adjustment of the extract. It includes extracts of all formulations that can be formed using the extract itself and the extract, such as preparations, purified products, or mixtures thereof.
- the noni fruit used in the manufacturing method of the present invention may be purchased commercially, or harvested or grown in nature, and noni fruit dried by natural or hot air drying method including all flesh, skin and seeds is used. .
- the extract of the present invention may be extracted from natural, hybrid or variant plants of the respective plants, and may be extracted from plant tissue culture.
- the method of extracting the extract is not particularly limited, and may be extracted according to a method commonly used in the art.
- Non-limiting examples of the extraction method include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, and the like, which may be performed alone or in combination of two or more methods.
- an extract was prepared using stirring extraction.
- the type of extraction solvent used to extract the noni fruit in the production method of the present invention is ethanol.
- Ethanol extraction i.e., alcohol extraction
- the concentration of ethanol in step b) is 10 (w/w)% to 95 (w/w)%, more preferably 10 (w/w)% to 60 (w/w) )%, more preferably 20 (w/w)% to 60 (w/w)%, most preferably 20 (w/w)% to 50 (w/w)%.
- a solvent extract may be prepared by extracting the dried noni fruit one or more times using the solvent, and a dry extract obtained by freeze drying or spray drying after distilling the solvent extract under reduced pressure may be prepared. have.
- the present inventors used purified water, 10 (w/w)% ethanol, 30 (w/w)% ethanol, 50 (w/w)% ethanol, 70 (w/w)% ethanol and Noni fruit extract was prepared using 95 (w/w)% ethanol, respectively, and 10 (w/w)%, 30 (w/w)%, and 50 (w/w) in various solvent extracts as shown in FIG. 2 )% ethanol solvent extract showed a high total iridoide content.
- deacetylasperulosidic acid DAA
- the 10 (w/w)% ethanol extract had excellent TNF- ⁇ production effect, which is excellent when the total iridoide content is high. Although it exhibits an immunity enhancing effect, it suggests that the total iridoide content and the immunity enhancing effect are not directly proportional.
- fraction means a result obtained by performing fractionation in order to separate a specific component or a specific component group from a mixture containing several different constituents.
- the fractionation method for obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art.
- a non-limiting example of the fractionation method may include a method of obtaining a fraction from the extract by treating an extract obtained by extracting the dried noni fruit with a predetermined solvent.
- the type of solvent used to obtain the fraction is purified water.
- the content of physiologically active substances exhibiting immunity enhancing activity, including iridoid decreases rapidly, and the intended physiological activity may not appear.
- the noni fruit extract prepared using 30 (w/w)% ethanol as an extraction solvent is purified water, 10 (w/w)% ethanol, 30 (w/w) % Ethanol and 70 (w/w)% ethanol were fractionated and purified for each compartment, and each fraction was treated with the macrophage line RAW264.7 to confirm the TNF- ⁇ production effect.
- FIG. 6 it was confirmed that the TNF- ⁇ production effect of fraction 1 (Frc-01), which is a purified water fraction, is the most excellent, and the same effect is insufficient in other fractions.
- the present inventors confirmed the molecular weight by performing GPC (Gel Permeation Chromatography) analysis in order to identify substances that substantially exhibit immunity enhancing efficacy in the purified water fraction, and as shown in FIG. 7, polysaccharides having a molecular weight of 10 kDa or more are immune. It was confirmed that it is a practical active ingredient showing enhancement efficacy.
- GPC Gel Permeation Chromatography
- the 10 (w/w)% ethanol extract was compared to the 30 (w/w)% and 50 (w/w)% ethanol extracts.
- the id content is low, the content of polysaccharides having a molecular weight of 10 kDa or more is higher than those of these extracts, and as a result, it can be interpreted as showing the most excellent immune enhancing effect.
- the present invention also provides a pharmaceutical composition for improving immunity and/or a health functional food composition comprising the extract of noni fruit containing high iridoid prepared by the above-described manufacturing method or a fraction thereof.
- the noni fruit extract or a fraction thereof can enhance both innate immunity or acquired immunity.
- the composition of the present invention is Ethanol in a concentration range different from the ethanol concentration used as the extraction solvent may be used in a method for efficiently extracting the iridoid.
- the composition for enhancing immunity of the present invention is 5 (w/w)% to 50 (w/w)% ethanol, more preferably 5 (w/w)% to 40 (w/w)% ethanol, most Preferably, it may include a noni fruit extract prepared using 5 (w/w)% to 30 (w/w)% ethanol as an extraction solvent.
- composition for enhancing immunity of the present invention may include a purified water fraction of 5 (w/w)% to 50 (w/w)% ethanol Noni fruit extract.
- the purified water fraction may be obtained by performing open column chromatography on the concentrate of 5 (w/w)% to 50 (w/w)% ethanol Noni fruit extract using purified water as an eluent, and at this time, open column
- the synthetic resin to be filled in is preferably a hydrophobic synthetic resin.
- the purified water fraction contained in the composition for enhancing immunity of the present invention was a polysaccharide having a molecular weight of 10 kDa or more.
- the purified water fraction contained in the composition for enhancing immunity of the present invention was a polysaccharide having a molecular weight of 10 kDa or more.
- the present invention further comprises the steps of: a) crushing noni fruit; b) adding 5 (w/w)% to 50 (w/w)% ethanol of 5 to 15 times the weight of the pulverized product to the pulverized product; And c) extracting the extract at 60° C. to 80° C. for 1 hour to 8 hours to prepare an extract. It provides a method for preparing a noni fruit extract or a fraction thereof containing a high immune enhancing active substance.
- the method for preparing a noni fruit extract or a fraction thereof containing a high immune enhancing active substance of the present invention may further include the step of: d) fractionating the obtained extract with purified water.
- step d the content of physiologically active substances exhibiting immunity enhancing activity, including iridoid, is rapidly reduced, so that the intended physiological activity may not appear.
- the immunostimulating active substance may be an iridoid and a polysaccharide having a molecular weight of 10 kDa or more, and the iridoid is diacetylasperuloside It may be one or more selected from the group consisting of acids (Deacetylasperulosidic acid, DAA), asperulosidic acid (ASPA), and asperuloside (ASP).
- DAA Deacetylasperulosidic acid
- ASPA asperulosidic acid
- ASP asperuloside
- the concentration range of ethanol from which the immune-promoting active substance can be most efficiently extracted is 5 (w/w)% to 50 (w/w)%, preferably 5 (w/w)% to 40 (w/w)%, more preferably 5 (w/w)% to 30 (w/w)%, most preferably 5 (w/w)% to 10 (w/w)%. .
- the pharmaceutical composition of the present invention may additionally include a pharmaceutically acceptable carrier.
- the pharmaceutical composition of the present invention can be prepared in a pharmaceutical formulation using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
- the pharmaceutical composition of the present invention is formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injectable solutions according to conventional methods.
- a suitable carrier, excipient, and diluent commonly used in the preparation of the composition may be further included.
- carriers that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like, but are not limited thereto.
- it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations contain at least one excipient, such as starch, calcium carbonate, and sucrose. ) Or lactose (lactose), gelatin, etc. are mixed to prepare. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc., and various excipients such as humectants, sweeteners, fragrances, preservatives, etc., in addition to water and liquid paraffin, which are commonly used simple diluents. have.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
- injectable ester such as ethyl oleate
- a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like may be used.
- administering means introducing the pharmaceutical composition of the present invention to a patient by any suitable method.
- the method of administration of the pharmaceutical composition according to the present invention is not particularly limited, and may be followed by a method commonly used in the art.
- the mode of administration is not limited as long as it can reach the target tissue, but may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, topically, or intranasally.
- the pharmaceutical composition according to the present invention may be prepared in various formulations according to the intended administration method.
- the pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount.
- the "pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type and severity of the individual, age, sex, type of infected virus, drug Activity, sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field.
- a typical daily dosage of the pharmaceutical composition according to the present invention may be appropriately selected by a person skilled in the art, and may be administered once or dividedly several times.
- composition of the present invention may be administered daily or intermittently, and the number of administrations per day may be administered once or divided into 2-3 times.
- composition of the present invention may be used alone or in combination with other drug treatments to enhance immunity. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and can be easily determined by a person skilled in the art.
- the pharmaceutical composition of the present invention can be administered to an individual in need of enhancing immunity to enhance immunity.
- the term "individual” refers to all animals including humans who have or are likely to develop metabolic diseases.
- the animals may be mammals such as cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, etc. in need of treatment for symptoms similar to humans, but are not limited thereto.
- the health functional food composition of the present invention includes the form of pills, powders, granules, needles, tablets, capsules or liquids, and as foods to which the composition of the present invention can be added, for example, various foods, such as For example, there are beverages, gum, tea, vitamin complexes, and dietary supplements.
- other ingredients other than those containing the noni fruit extract or fractions thereof are not particularly limited, and various herbal extracts, food supplementary additives, natural carbohydrates, etc. May contain as an additional component.
- the food additives include food additives conventional in the art, such as flavoring agents, flavoring agents, coloring agents, fillers, stabilizers, and the like.
- natural carbohydrates examples include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- natural flavoring agents for example, rebaudioside A, glycyrrhizin, etc.
- synthetic flavoring agents sacharin, aspartame, etc.
- the health functional food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents and fillers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid. And salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like. In addition, it may contain flesh for the manufacture of natural fruit juice and fruit juice beverages and vegetable beverages. These components may be used independently or in combination.
- the health supplements include health functional foods and health foods.
- Functional food is the same term as food for special health use (FoSHU), and is a medicine that is processed so that the bioregulatory function effectively appears in addition to nutrition supply, and has high medical effect.
- the term “function (sex)” means obtaining useful effects for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body.
- the food of the present invention can be prepared by a method commonly used in the art, and during the production, raw materials and ingredients commonly added in the art may be added to prepare the food product.
- the formulation of the food may be prepared without limitation as long as it is a formulation recognized as a food.
- the health functional food composition of the present invention can be prepared in various forms of formulation, and unlike general drugs, it has the advantage of not having side effects that may occur when taking the drug for a long time by using food as a raw material.
- the present invention also provides a method for enhancing immunity, comprising administering an effective amount of a noni fruit extract or a fraction thereof to an individual in need thereof.
- the individual may be in a state of reduced immune function.
- various immune diseases such as asthma, seasonal or perennial rhinitis, allergic sinusitis, conjunctivitis, atopic dermatitis, urticaria, hemolysis of red blood cells, acute glomerulonephritis, etc. may have occurred due to a decrease in immune function.
- the noni fruit extract or a fraction thereof may be administered to a healthy individual having a normal immune function in order to prevent diseases associated with a decrease in immune function.
- the present invention also provides a use of a noni fruit extract or a fraction thereof in the manufacture of a medicament for preventing or treating diseases associated with immunity enhancement or immunity reduction.
- the dried noni fruit was pulverized into 40 to 100 mesh to increase extraction efficiency. After 10 times the weight of the pulverized pulverized product, 30 (w/w)% ethanol was added to the extractor, and the dried noni fruit pulverized product as a raw material was gradually added. After the raw material input was completed, the temperature was stirred and extracted at 80° C. for 4 hours. After that, filtration was performed using Whatman No.4 paper filter paper. The filtered extract was concentrated under reduced pressure at 60 to 70°C to prepare a concentrate, and then freeze-dried to prepare a powder (yield 28%).
- a Noni extract was prepared in the same manner as in Example 1, except that 10 (w/w)% ethanol was used as the extraction solvent (yield 24%).
- a Noni extract was prepared in the same manner as in Example 1, except that 50 (w/w)% ethanol was used as the extraction solvent (yield 21%).
- Noni extract was prepared in the same manner as in Example 1, except that purified water was used as the extraction solvent (yield 17%).
- Noni extract was prepared in the same manner as in Example 1, except that 70 (w/w)% ethanol was used as the extraction solvent (yield 15%).
- Noni extract was prepared in the same manner as in Example 1, except that 95 (w/w)% ethanol was used as the extraction solvent (yield 7%).
- Each extract was aliquoted by about 100 mg into a 50 ml volumetric flask, and then distilled water was added according to the dosage line and completely dissolved.
- the test solution filtered through a 0.45 ⁇ m syringe filter was used for analysis.
- the HPLC analysis method is shown in Table 2 below, and the analyzed result values are shown in Fig. 2 in terms of the extraction yield of each Example and Comparative Example, and the HPLC profile of the extract of Example 1 is shown in Fig. 3.
- TNF- ⁇ derived from macrophages In order to confirm the immunity enhancing effect for each of the extracts prepared through Examples 1 to 3 and Comparative Examples 1 to 3, in this example, the production of TNF- ⁇ derived from macrophages according to the extract treatment was measured.
- TNF is a cytokine that mediates and regulates innate immunity. It is also secreted by antigen-stimulated T lymphocytes, NK cells, and mast cells, but activated macrophages are the main producing cells. Production was measured.
- the cultured mouse macrophage cell line RAW264.7 (KCLB#40071, Korea Cell Line Bank) was adjusted to a concentration of 1 ⁇ 10 6 cells/ml using RPMI1640 medium (Gibco, Cat#11875-093), and then a 96-well plate Was inoculated, and pre-incubated for 18 hours at 5% CO 2 and 37°C. Thereafter, the medium was removed, and cultured by treating the medium containing each extract at a concentration of 50 and 200 ⁇ g/mL, respectively.
- TNF- ⁇ ELISA enzyme-linked immunosorbent assay
- Noni fruit extract of Example 1 contains the excellent immune enhancing effect and the highest total iridoide, additional fractions were prepared and selected to confirm clear active ingredients for this target. I did.
- Example 1 30 (w/w)% ethanol Noni fruit extract of Example 1 was added to an open column filled with TRILITE ® GSH-20 resin (hydrophobic synthetic resin), and purified water, 10 ( In the conditions of w/w)% ethanol, 30 (w/w)% ethanol, and 70 (w/w)% ethanol, the 30 (w/w)% ethanol Noni fruit extract of Example 1 was fractionated and purified for each compartment. The immune enhancing activity for each fraction was confirmed in the same manner as in Example 4, and the results are shown in FIG. 6.
- the purified water fraction fraction 1 (Frc-01) showed the highest immune enhancing effect, the other fractions were confirmed that the immune enhancing effect was insufficient. Through this, it can be seen that the hydrophilic substrate exhibits an immunity enhancing effect in a higher portion.
- the purified water fraction contains polysaccharides having an average molecular weight of about 10 kDa or more, and these polysaccharides are practically active ingredients exhibiting immunity enhancing efficacy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
실시예/비교예 | 추출 용매 |
실시예 1 | 30 (w/w)% 에탄올 |
실시예 2 | 10 (w/w)% 에탄올 |
실시예 3 | 50 (w/w)% 에탄올 |
비교예 1 | 정제수 |
비교예 2 | 70 (w/w)% 에탄올 |
비교예 3 | 95 (w/w)% 에탄올 |
구분 | 상세 내용 |
기기 | Agilient |
검출기 | UV(DAD) |
파장 | 238nm |
컬럼 | InfinityLab Poroshell 120 EC-C18 (150×4.6mm, 5㎛) |
이동상 | A: 증류수에 용해된 0.1% 포름산B: 아세토니트릴에 용해된 0.1% 포름산 |
유속 | 0.5ml/분 |
주입 용량 | 10㎕ |
오븐 온도 | 40℃ |
실행 시간 | 40분 |
구분 | 상세내용 |
기기 | Tosh사 EcoSEC HLC-8320 GPC |
검출기 | RI-검출기 |
컬럼 | 2ХTSKgel GMPWxl + TSKgel G2500PWxl (7.8Х300mm) |
이동상 | 0.1M NaNo3 |
유속 | 1.0ml/분 |
주입 용량 | 100㎕, 3mg/ml |
오븐 온도 | 40℃ |
Claims (25)
- a) 노니 열매를 분쇄하는 단계;b) 분쇄물 중량 대비 5 내지 15배수의 10(w/w)% 내지 60(w/w)% 에탄올을 분쇄물에 투입하는 단계; 및c) 60℃ 내지 100℃에서 1시간 내지 8시간 동안 추출하여 추출물을 제조하는 단계;를 포함하는 이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법.
- 제1항에 있어서, 상기 b) 단계의 에탄올은 20(w/w)% 내지 60(w/w)% 에탄올인 이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법.
- 제1항에 있어서, 상기 c) 단계의 추출은 교반 추출인 이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법.
- 제1항에 있어서, d) 추출물을 여과 및 농축하여 농축액을 제조하는 단계를 더 포함하는 이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법.
- 제1항에 있어서, 상기 이리도이드는 디아세틸아스페룰로사이드산(Deacetylasperulosidic acid, DAA), 아스페룰로사이드산(Asperulosidic acid, ASPA) 및 아스페룰로사이드(Asperuloside, ASP)로 이루어진 군으로부터 선택된 1종 이상인 이리도이드 고함유 노니 열매 추출물의 제조방법.
- 노니 열매 추출물 또는 이의 분획물을 포함하는 면역 증진용 약학 조성물.
- 제6항에 있어서, 상기 추출물은 5(w/w)% 내지 50(w/w)% 에탄올을 추출 용매로 하여 제조된 것인 면역 증진용 약학 조성물.
- 제6항에 있어서, 상기 분획물은 5(w/w)% 내지 50(w/w)% 에탄올 추출물의 정제수 분획물인 것인 면역 증진용 약학 조성물.
- 제8항에 있어서, 상기 에탄올 추출물 및 이의 정제수 분획물은 10kDa 이상의 분자량을 갖는 다당체를 포함하는 면역 증진용 약학 조성물.
- 노니 열매 추출물 또는 이의 분획물을 포함하는 면역 증진용 건강기능식품 조성물.
- 제10항에 있어서, 상기 추출물은 5(w/w)% 내지 50(w/w)% 에탄올을 추출 용매로 하여 제조된 것인 면역 증진용 건강기능식품 조성물.
- 제10항에 있어서, 상기 분획물은 5(w/w)% 내지 50(w/w)% 에탄올 추출물의 정제수 분획물인 것인 면역 증진용 건강기능식품 조성물.
- 제12항에 있어서, 상기 에탄올 추출물 및 이의 정제수 분획물은 10kDa 이상의 분자량을 갖는 다당체를 포함하는 면역 증진용 건강기능식품 조성물.
- 노니 열매 추출물 또는 이의 분획물을 유효량으로 이를 필요로 하는 개체에게 투여하는 것을 포함하는, 면역 증진 방법.
- 제14항에 있어서, 상기 추출물은 5(w/w)% 내지 50(w/w)% 에탄올을 추출 용매로 하여 제조된 것인, 면역 증진 방법.
- 제14항에 있어서, 상기 분획물은 5(w/w)% 내지 50(w/w)% 에탄올 추출물의 정제수 분획물인 것인, 면역 증진 방법.
- 제16항에 있어서, 상기 에탄올 추출물 및 이의 정제수 분획물은 10kDa 이상의 분자량을 갖는 다당체를 포함하는, 면역 증진 방법.
- 면역 증진을 위한 약제의 제조 시 노니 열매 추출물 또는 이의 분획물의 용도.
- 제18항에 있어서, 상기 추출물은 5(w/w)% 내지 50(w/w)% 에탄올을 추출 용매로 하여 제조된 것인, 용도.
- 제18항에 있어서, 분획물은 5(w/w)% 내지 50(w/w)% 에탄올 추출물의 정제수 분획물인 것인, 용도.
- 제20항에 있어서, 상기 에탄올 추출물 및 이의 정제수 분획물은 10kDa 이상의 분자량을 갖는 다당체를 포함하는, 용도.
- a) 노니 열매를 분쇄하는 단계;b) 분쇄물 중량 대비 5 내지 15배수의 5(w/w)% 내지 50(w/w)% 에탄올을 분쇄물에 투입하는 단계; 및c) 60℃ 내지 80℃에서 1시간 내지 8시간 동안 추출하여 추출물을 제조하는 단계;를 포함하는 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법.
- 제22항에 있어서, d) 수득된 추출물을 정제수로 분획하는 단계를 추가로 포함하는 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법.
- 제22항에 있어서, 상기 면역증진 활성물질은 이리도이드 및 10kDa 이상의 분자량을 갖는 다당체인 것인 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법.
- 제24항에 있어서, 상기 이리도이드는 디아세틸아스페룰로사이드산(Deacetylasperulosidic acid, DAA), 아스페룰로사이드산(Asperulosidic acid, ASPA) 및 아스페룰로사이드(Asperuloside, ASP)로 이루어진 군으로부터 선택되는 1종 이상인 것인 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/257,222 US11628195B2 (en) | 2019-06-03 | 2020-06-02 | Method for preparing iridoid-rich noni fruit extract or fraction thereof, method for preparing immune-enhancing active material-rich noni fruit extract or fraction thereof and use of noni fruit extract or fraction thereof |
AU2020264340A AU2020264340B2 (en) | 2019-06-03 | 2020-06-02 | Method of preparing noni fruit extract containing high iridoid content or a fraction thereof, method of preparing noni fruit extract containing high content of immune-enhancing active substance or a fraction thereof and use of noni fruit extract or a fraction thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0065431 | 2019-06-03 | ||
KR1020190065431A KR102082106B1 (ko) | 2019-06-03 | 2019-06-03 | 이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법, 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법 및 노니 열매 추출물 또는 이의 분획물을 포함하는 면역 증진용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020246777A1 true WO2020246777A1 (ko) | 2020-12-10 |
Family
ID=69647375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/007155 WO2020246777A1 (ko) | 2019-06-03 | 2020-06-02 | 이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법, 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법 및 노니 열매 추출물 또는 이의 분획물의 용도 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11628195B2 (ko) |
KR (1) | KR102082106B1 (ko) |
AU (1) | AU2020264340B2 (ko) |
WO (1) | WO2020246777A1 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102082106B1 (ko) * | 2019-06-03 | 2020-02-27 | 코스맥스엔비티 주식회사 | 이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법, 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법 및 노니 열매 추출물 또는 이의 분획물을 포함하는 면역 증진용 조성물 |
KR102131602B1 (ko) | 2020-02-19 | 2020-07-08 | 코스맥스엔비티 주식회사 | 배초향 및 감초 추출물을 유효성분으로 함유하는 미세먼지에 의한 호흡기 질환 예방 또는 치료용 조성물 |
KR102164943B1 (ko) | 2020-06-18 | 2020-10-13 | 주식회사 휴먼바이오 | 노니 열매에 함유된 생리활성 물질 5종의 동시분석방법 |
US20240016876A1 (en) * | 2020-11-17 | 2024-01-18 | Cosmax Nbt, Inc. | Composition for hangover relief comprising noni fruit extract or fraction thereof and use thereof |
CN116528690A (zh) * | 2020-11-17 | 2023-08-01 | 科丝美诗纽芝丽株式会社 | 包含诺丽果提取物或其分馏物的解酒用组合物及其用途 |
KR102424724B1 (ko) * | 2020-11-17 | 2022-07-25 | 코스맥스엔비티 주식회사 | 노니 열매 추출물 또는 이의 분획물을 포함하는 숙취 해소용 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013520515A (ja) * | 2010-02-23 | 2013-06-06 | モリンダ インコーポレーテッド | モリンダ・シトリフォリアおよびイリドイドをベースとする処方物 |
KR101949617B1 (ko) * | 2017-12-08 | 2019-05-20 | 주식회사 풀무원 | 이리도이드 고함유 노니 부산물의 추출물 제조방법 |
KR102082106B1 (ko) * | 2019-06-03 | 2020-02-27 | 코스맥스엔비티 주식회사 | 이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법, 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법 및 노니 열매 추출물 또는 이의 분획물을 포함하는 면역 증진용 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090072555A (ko) | 2007-12-28 | 2009-07-02 | 주식회사 노니원 | 노니열매의 농축액 제조방법 |
US11160840B2 (en) | 2016-12-30 | 2021-11-02 | Industry-Academic Cooperation Foundation, Yonsei University | Composition for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
CN108888556B (zh) * | 2018-07-31 | 2021-06-04 | 北京东方淼森生物科技有限公司 | 一种诺丽活性载体组合物、制备方法及应用 |
CN109198635A (zh) * | 2018-08-17 | 2019-01-15 | 吉林工贸学校 | 一种具有增强免疫力功能的保健食品及其制备方法 |
-
2019
- 2019-06-03 KR KR1020190065431A patent/KR102082106B1/ko active IP Right Grant
-
2020
- 2020-06-02 WO PCT/KR2020/007155 patent/WO2020246777A1/ko active Application Filing
- 2020-06-02 AU AU2020264340A patent/AU2020264340B2/en active Active
- 2020-06-02 US US17/257,222 patent/US11628195B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013520515A (ja) * | 2010-02-23 | 2013-06-06 | モリンダ インコーポレーテッド | モリンダ・シトリフォリアおよびイリドイドをベースとする処方物 |
KR101949617B1 (ko) * | 2017-12-08 | 2019-05-20 | 주식회사 풀무원 | 이리도이드 고함유 노니 부산물의 추출물 제조방법 |
KR102082106B1 (ko) * | 2019-06-03 | 2020-02-27 | 코스맥스엔비티 주식회사 | 이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법, 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법 및 노니 열매 추출물 또는 이의 분획물을 포함하는 면역 증진용 조성물 |
Non-Patent Citations (2)
Title |
---|
MURATA, K.: "Activation of cell -mediated immunity by Morinda citrifolia fruit extract and its constituents", NATURAL PRODUCT COMMUNICATIONS., 4 September 2014 (2014-09-04), pages 445 - 450 * |
NAYAK, S.: "Immunostimulant activity of noni (Morinda citrifolia) on T and B lymphocytes", PHARMACEUTICAL BIOLOGY, vol. 48, no. 7, 3 June 2010 (2010-06-03) - July 2010 (2010-07-01), pages 724 - 731, XP055769454 * |
Also Published As
Publication number | Publication date |
---|---|
US11628195B2 (en) | 2023-04-18 |
AU2020264340B2 (en) | 2022-12-01 |
AU2020264340A1 (en) | 2020-12-17 |
US20220080018A1 (en) | 2022-03-17 |
KR102082106B1 (ko) | 2020-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020246777A1 (ko) | 이리도이드 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법, 면역증진 활성물질 고함유 노니 열매 추출물 또는 이의 분획물의 제조방법 및 노니 열매 추출물 또는 이의 분획물의 용도 | |
WO2010137846A2 (ko) | 사포닌의 생체 이용률 증진 조성물 | |
WO2015002391A1 (ko) | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 | |
WO2016153211A2 (ko) | 감귤류 과피 추출물의 제조방법 및 간 손상 예방, 개선 또는 치료용 조성물 | |
WO2016032249A1 (ko) | 모새나무 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물 | |
WO2013105693A1 (ko) | 벼 겉껍질 및 보리 겉껍질 추출물을 유효성분으로 포함하는 약학 조성물 | |
WO2017014502A1 (ko) | 해당화 꽃 추출물을 유효성분으로 포함하는 il-6 매개성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2017183902A1 (ko) | 인진, 지유 및 울금 추출물 및 항바이러스제를 유효성분으로 포함하는 간질환 예방 또는 치료용 조성물 | |
WO2016190566A2 (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
WO2013141581A1 (ko) | 댕댕이나무열매 추출물을 유효성분으로 함유하는 허혈성 뇌혈관 질환의 예방 또는 개선용 약학적 조성물 또는 건강식품 | |
WO2020242113A1 (ko) | 인디안구스베리 추출물과 새싹보리 추출물의 복합물(ib복합물)을 유효성분으로 포함하는 비만 및/또는 당뇨를 동반하는 대사증후군의 예방, 개선 치료용 조성물 | |
WO2020256464A1 (ko) | 항염 활성을 갖는 아피오스 아메리카나 괴경 추출물의 분획물의 알코올성 위염 예방 또는 치료제로서의 용도 및 이의 제조방법 | |
WO2017099509A1 (ko) | 가시박 추출물을 유효성분으로 포함하는 간 질환의 치료 또는 예방용 조성물 | |
WO2020080673A1 (ko) | 병풀 추출물을 포함하는 망막 질환의 예방 또는 치료용 조성물 | |
WO2014133286A1 (ko) | 한인진 및 울금의 추출물을 유효성분으로 포함하는 비만 관련 질환의 예방, 억제 또는 치료용 조성물 | |
WO2012033329A2 (ko) | 미나리 추출물을 유효성분으로 함유하는 학습능력 또는 기억력 장애 예방 또는 치료용 조성물 및 그 제조방법 | |
WO2011046411A2 (ko) | 뇌신경 세포 보호 활성 및 아세틸콜린에스테라제 저해 활성을 갖는 율피 추출물 및 그의 용도 | |
WO2018038293A1 (ko) | 괴각 추출물을 유효성분으로 함유하는 퇴행성 뇌질환의 예방 및 치료용 약학적 조성물 | |
WO2017213437A1 (ko) | 가시박 추출물 또는 이의 분획물을 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 조성물 | |
KR101854180B1 (ko) | 감귤류 과피 추출물을 포함하는 간 손상 예방 또는 개선용 건강기능식품 | |
WO2022216107A1 (ko) | 담팔수 추출물 또는 이의 정제물을 유효성분으로 함유하는 항암용 조성물 | |
WO2023121321A1 (ko) | 항암 활성을 갖는 아사로이독사진 b의 용도 | |
WO2021085741A1 (ko) | 번행초를 유효성분으로 포함하는 알츠하이머성 치매 개선 또는 치료용 조성물 | |
WO2021215885A1 (ko) | 풍뎅이 유충 또는 이의 추출물을 유효성분으로 포함하는 배변 기능 개선용 조성물 | |
WO2022182199A1 (ko) | 블랙커런트 열수 추출물을 포함하는 비알코올성 지방간 질환의 예방, 개선 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2020264340 Country of ref document: AU Date of ref document: 20200602 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20818243 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22.04.2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20818243 Country of ref document: EP Kind code of ref document: A1 |